Therapeutic | Nimotuzumab |
Target | EGFR |
Heavy Chain | QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT |
100% seqID Fv Structure | 3gkw [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 3gkw [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Approved |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2005 |
INN Year Recommended | 2006 |
Companies Involved | Biocon Biopharmaceuticals, Biotech Pharmaceutical, Center of Molecular Immunology, CIMYM, Daiichi Sankyo Inc, Eurofarma, Gilead Sciences, Innogene Kalbiotech, InnoMab, Kuhnil Pharmaceutical Company, Laboratorios Pisa, Oncoscience |
Conditions Approved | Anaplastic astrocytoma, Brain cancer, Glioblastoma, Glioma, Head and neck cancer, Nasopharyngeal cancer, Oesophageal cancer |
Conditions Active | Cervical cancer, Gastric cancer, Non-small cell lung cancer, Pancreatic cancer, Breast cancer, Colorectal cancer |
Conditions Discontinued | |
Notes | na |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]